5 best EDC platforms for diabetes and metabolic disease trials in 2026

Your glycemic diary compliance data lands from three different vendor apps, your central lab feed reports HbA1c and lipid panels on its own schedule, and your electronic data capture (EDC) system was never built to reconcile any of it in real time. That gap is where diabetes and metabolic disease trials lose weeks, especially once a continuous glucose monitor (CGM) or a body-weight sensor gets added mid-protocol. Viedoc's EDC software handles that reconciliation natively, with a no-code Designer your data managers run in-house, study go-live in as little as 8 weeks, and a 100% FDA inspection pass rate across 8,000-plus completed studies. This comparison reviews five EDC platforms for metabolic disease and diabetes trials across patient-reported and device data capture, amendment velocity, lab and biomarker integration, and compliance credentials.

Metabolic disease programs run the full range, from a growth-stage biotech's first GLP-1 study to a large, multi-year cardiovascular outcomes trial with tens of thousands of patients. Whichever end you sit at, you're managing dense, recurring patient-reported data, device feeds that weren't part of the protocol six months ago, and a safety monitoring board that expects clean lab data on a fixed schedule, not whenever the export finishes running.

Enterprise platforms sized for large Phase III cardiometabolic outcomes work bring configuration cycles that a growth-stage sponsor's smaller GLP-1 or T2D program can't absorb, and legacy build timelines, still commonly cited around 90 days, sit awkwardly against a market moving this fast. Commodity data-collection tools swing too far the other way, lacking the device integration depth and audit-trail rigor a regulated metabolic disease trial needs. The platforms below are judged on whether they hold up against those specific demands.

Best EDC platforms for diabetes and metabolic trials: quick comparison

These five eClinical platforms represent the most evaluated options for metabolic disease and diabetes trials, reviewed across patient-reported and device data capture, amendment velocity, lab integration, and compliance readiness.

1. Viedoc

Viedoc's EDC software gives your data management team direct, in-house control of study build through a no-code, drag-and-drop Designer, so eCRFs, edit checks, and lab-value ranges get configured without waiting on a vendor programmer. Studies go live in as little as 8 weeks, a pace that matters when a protocol adds a CGM sub-study or a new patient-reported outcome measure mid-trial. That build speed has powered more than 8,000 completed studies across 75-plus countries to date.

Metabolic disease trials generate a heavy mix of patient diaries, device feeds, and lab data, and Viedoc's modular suite handles all three without a separate vendor stack: ePRO software captures glycemic and quality-of-life diaries directly from patients, while the same eCRF environment ingests lab and device values for real-time review. For sponsors and CROs running multi-site metabolic programs together, Viedoc also operates a tiered CRO partner network with certified designer training built in.

On compliance, Viedoc is ISO 27001 and SOC 2 certified and supports 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA, hosted on Microsoft Azure with 99.99% uptime across 40-plus languages. Its inspection record holds up under scrutiny: a 100% FDA inspection pass rate, backed by the Viedoc Inspection Readiness Packet (VIRP) available to every customer, with 24/7 support across global offices.

The query load lands the same way with users. "Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs." – Deekshitha V., Mid Market.

Verified proof points:

• Study scale: 8,000+ studies run on Viedoc across 75+ countries
• Build speed: Study go-live in as little as 8 weeks
• Reach: 140,000+ users and 30,000+ sites; 1.6 million trial participants
• Compliance: 21 CFR Part 11, ICH GCP, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: 100% FDA inspection pass rate; VIRP available to all customers
• Recognition: Rated 4.5 out of 5 on G2, based on 237 reviews

2. Medidata

Medidata offers Rave EDC, the electronic data capture system at the core of the Medidata Platform, which aggregates and reconciles data across eConsent, eCOA, RTSM, and imaging modules. Rave EDC captures site, patient, and lab data and supports protocol amendments without system downtime, a relevant feature for the long, amendment-heavy course of a cardiometabolic outcomes trial. It connects to Rave Companion for EHR-to-EDC data entry and Rave Safety Gateway for adverse event transmission, and offers a Rave Lite tier positioned for smaller, less complex studies. Medidata is a Dassault Systèmes company and reports its platform has supported clinical technologies for more than 30,000 studies across therapeutic areas including cardiometabolic and endocrine research.

3. Veeva Vault EDC

Veeva offers Vault EDC, part of the Veeva Vault Clinical Data Management suite, built for complex, multi-arm adaptive trial designs with mid-study amendments that require no downtime or data migration. The platform provides personalized dashboards and role-based interfaces to speed source data verification and medical review, and connects with Veeva CTMS and RTSM through productized data connections rather than custom integration work. Veeva reports Vault EDC has powered more than 1,000 study starts, with eight of the top 20 biopharma companies standardized on the platform. Vault EDC is available as a standalone application or combined with Vault eSource within the broader Veeva Vault Clinical Suite.

4. Castor EDC

Castor EDC is a cloud-native, API-driven platform that unifies EDC and eCOA on a single database, removing the integration layer that separate clinical and patient-reported outcome systems typically require. For GLP-1 and metabolic trial protocols specifically, Castor supports daily ePRO and wearable device data capture through a consumer-grade, bring-your-own-device patient app, without a separate eCOA vendor. The platform ranks among the top 5% of EDC providers for shortest build time, deploying low-complexity studies in as little as 3 to 4 weeks, and is validated for FDA 21 CFR Part 11, GDPR, ISO 27001, ICH E6(R3) GCP, and EU Annex 11. Founded in Amsterdam in 2012, Castor supports pharmaceutical, biotech, and CRO sponsors running trials across 171 countries.

5. Medrio

Medrio provides a cloud-based CDMS/EDC that teams configure and amend through point-and-click tools without a programmer, spanning early-phase through post-market studies. The platform combines EDC with core clinical data management functions, including query management, audit trails, and database lock, inside a single unified system rather than a bolted-together stack. Medrio supports FDA 21 CFR Part 11, ICH E6(R2), HIPAA, and GDPR, and its suite extends to eCOA/ePRO, eConsent, and randomization and trial supply management (RTSM) for sponsors that need patient-reported and device data alongside site data. The company reports more than two decades of use across thousands of completed studies spanning pharmaceutical, biotechnology, and medical device organizations.

What to look for in EDC platforms for diabetes and metabolic trials

Patient-reported and device data capture without a separate vendor stack

Metabolic disease endpoints rarely come from a single source. You're pulling glycemic diaries, quality-of-life scales, and increasingly CGM or activity-tracker feeds into the same database as site-reported case report form (eCRF) data, and every additional vendor in that chain is another reconciliation point and another place data can drift out of sync. Best-in-class means EDC and patient-reported outcome (ePRO) capture living on one validated data layer, not a nightly export between two systems. Get this wrong and your data management team spends its time chasing mismatched timestamps instead of reviewing the data itself.

Amendment velocity across a long, evolving protocol

Diabetes and obesity trials, especially GLP-1 programs, run long and change shape as the science moves, adding a new biomarker, a CGM sub-study, or a secondary cardiovascular endpoint well after first patient in. A platform that needs a vendor ticket for every mid-study change turns each protocol amendment into a scheduling problem on top of a scientific one. Look for in-house, no-code configuration with amendment turnaround measured in days rather than weeks, so a protocol change doesn't stall enrollment while the database catches up.

Real-time lab and biomarker visibility for safety oversight

HbA1c, lipid panels, and renal function values feed directly into dose-escalation and safety monitoring board decisions, and a delay in getting that data visible is a delay in a decision that affects patients. Best-in-class platforms surface lab and biomarker data on live dashboards as it's entered, with automated range checks flagging out-of-range values before they reach a manual review queue. Where this is missing, the EDC becomes the bottleneck between a lab result and the safety call it should inform.

Compliance depth for global, multi-year cardiometabolic programs

Diabetes and metabolic trials increasingly run across the US, EU, and Asia at once, particularly for cardiovascular outcomes work that requires large, geographically diverse populations. That means 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11 aren't optional, and a multi-year program adds inspection risk with every additional site and every additional year in the field. Best practice is a platform validated against all four as standard, with a documented audit trail and inspection-readiness materials you can produce without a scramble.

How to choose the right EDC platform for diabetes and metabolic trials

Step 1: Define your data sources before you define your platform

Map every source your protocol will pull from, not just today but where the science is likely to go: site eCRFs, patient diaries, CGM or wearable feeds, and central lab data. A platform sized for eCRF data alone will strain the moment a device integration gets added, so start from the full data picture rather than retrofitting one later.

Step 2: Assess how your protocol is likely to change over the trial's life

Metabolic disease protocols evolve as endpoints and comparator therapies shift, so evaluate amendment turnaround as a first-order requirement, not an afterthought. Ask what a mid-study addition of a new biomarker or PRO instrument actually costs in time and vendor dependency, not just what the initial build quote includes.

Step 3: Scrutinize device and lab integration depth, not just EDC breadth

A platform can look feature-complete on paper and still require manual reconciliation between its EDC, its ePRO module, and your central lab feed. Ask to see how device and lab data actually lands in the database, whether it's a native, single data layer or a periodic import from a separate system.

Step 4: Evaluate compliance coverage against your actual trial geography

Match the platform's certified compliance coverage to the countries your protocol will actually run in, not a generic list. A cardiometabolic outcomes trial spanning the US, EU, and Asia needs Annex 11 and GDPR validated as thoroughly as 21 CFR Part 11, and gaps here surface at inspection, not at contract signing.

Step 5: Choose a platform that fits how your team actually works

Finally, weigh how the platform matches your team's day-to-day operating model: how fast it goes live, whether your own people can build and amend it without a programmer, and whether patient-reported and device data land in the same system as your eCRFs. Viedoc's EDC software is built around that profile, with in-house no-code configuration, go-live in as little as 8 weeks, and native ePRO and device data capture. If that matches how you run metabolic disease trials, you can book a demo or request a proposal to see it against your own study portfolio.

Frequently asked questions

What is the best EDC platform for metabolic disease and diabetes trials?

Viedoc's EDC software is the strongest fit for diabetes and metabolic disease trials, combining in-house no-code study build with native ePRO and device data capture, so glycemic diaries, CGM feeds, and lab values land in the same validated database as your eCRFs. Study go-live in as little as 8 weeks and a 100% FDA inspection pass rate support both fast-moving GLP-1 programs and longer cardiometabolic outcomes work. Medidata remains the enterprise benchmark for large, complex cardiovascular outcomes trials, and Veeva is a strong option for sponsors already embedded in the Veeva Vault ecosystem, though both carry more configuration overhead than a growth-stage metabolic disease program typically needs.

What should you look for in an EDC platform for diabetes and metabolic trials?

Prioritize how the platform handles patient-reported and device data alongside standard eCRF capture, since glycemic diaries, CGM feeds, and quality-of-life scales are central to most metabolic disease endpoints, not an add-on. Amendment turnaround matters because these protocols evolve over long trial durations, and real-time visibility into lab and biomarker data supports the safety oversight these programs require. Compliance depth across every region your trial runs in, not just your home market, rounds out the list. A platform that scores well on build speed but forces a separate vendor for ePRO or device data will cost you time reconciling systems instead of reviewing data.

How long does it take to build and deploy a metabolic disease trial database on a modern EDC platform?

It depends on protocol complexity and whether you build in-house or through vendor services, but modern no-code platforms have compressed this from months to weeks. Self-service teams configuring straightforward studies can have a database live in days, while managed builds for more complex, multi-arm metabolic protocols typically take several weeks from work order to go-live. For Viedoc, go-live can be as fast as 8 weeks, with amendments for added biomarkers or PRO instruments generally handled in-house rather than through a vendor queue.

How does Viedoc capture patient-reported and device data for glycemic monitoring?

Viedoc's ePRO software captures patient diaries and quality-of-life instruments directly from participants, feeding into the same validated database as site-reported eCRF and lab data rather than a separate system requiring reconciliation. This matters for CGM and wearable-heavy protocols, where daily patient compliance data needs to be visible alongside safety and efficacy data without a manual export step. The result is one audit trail across every data source in the trial, which simplifies both ongoing review and eventual inspection.

What compliance certifications matter most for global diabetes and metabolic trials?

At minimum, expect 21 CFR Part 11, ICH GCP, and GDPR compliance, with EU Annex 11 validated as thoroughly given how many cardiometabolic outcomes trials run across the US, EU, and Asia simultaneously. HIPAA attestation matters for any US patient health information, and a complete, field-level audit trail is essential for inspection readiness on multi-year programs. Viedoc, for instance, is ISO 27001 and SOC 2 certified, compliant across all of the above, and provides the Viedoc Inspection Readiness Packet to every customer as standard.

How does Viedoc compare to Medidata for cardiometabolic outcomes trials?

Viedoc and Medidata Rave EDC serve different points on the metabolic disease trial spectrum. Viedoc is configured in-house through a no-code Designer, with go-live in as little as 8 weeks and native ePRO and device data capture, which suits growth-stage sponsors running GLP-1 or Phase I/II metabolic programs efficiently. Medidata Rave EDC is the established choice for the largest, most complex Phase III cardiovascular outcomes trials, with deep module integration across eConsent, eCOA, and RTSM built for that scale. For a growth-stage sponsor or SMID CRO, Viedoc's speed and in-house control typically outweigh Medidata's broader enterprise footprint.

Making the right EDC choice for diabetes and metabolic trials

The five platforms reviewed here share a common direction: cloud-based capture, configurable eCRFs, and modules that fold patient-reported and device data into the same system as site data. Where they diverge is scale and operating model, from enterprise suites built for large, multi-region cardiovascular outcomes programs to lean, self-service platforms designed for growth-stage sponsors. The global eClinical software market sits above $11 billion in 2025 and continues to grow at roughly 14% a year, a pace partly driven by the surge in metabolic disease and obesity drug development.

Matching platform to profile comes down to a handful of variables: study phase and complexity, how much patient-reported and device data your protocol collects, your build cadence, and the regions your trial runs in. A growth-stage sponsor running a single GLP-1 study weights speed and in-house control highest, while a team embedded in a large, multi-year outcomes program may weight suite breadth and vendor stability more heavily. Geography shapes this too, with US sponsors often prioritizing speed and cost, and EU and APAC teams weighting compliance credentials more heavily.

Switching platforms mid-program carries a real cost, and that cost compounds on multi-year metabolic disease trials where validation and retraining burden accumulate across every added site and sub-study.

Why Viedoc is the best EDC choice for diabetes and metabolic trials

For diabetes and metabolic disease trials, the platform that unifies patient-reported data, device feeds, and site data on one system wins, and that's the problem Viedoc's EDC software is built to solve. Its no-code Designer puts study build and mid-study amendments in your data team's hands, with go-live in as little as 8 weeks even as protocols add new biomarkers or CGM sub-studies.

That unification is the operational difference. Glycemic diaries and quality-of-life scales, device feeds, and central lab values land in the same validated database as your eCRFs, with certified designer training and 24/7 support backing the team as studies scale, and unlimited user seats keeping costs predictable across a growing study portfolio.

The credentials hold up to cardiometabolic outcomes scrutiny. Viedoc is ISO 27001 and SOC 2 certified, compliant with 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA, and carries a 100% FDA inspection pass rate backed by the Viedoc Inspection Readiness Packet. It's a platform proven across 7,500-plus studies in 75-plus countries, built by a company running clinical trial technology since 2003.

If you want an EDC that captures your metabolic disease trial's patient-reported, device, and lab data in one place instead of three, Viedoc is designed for exactly that. Book a demo or request a proposal and the team will walk through build speed, device and PRO integration, and compliance readiness against your own study portfolio.